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HIGHLIGHTS 
 Tuberculin skin test (TST) is over a century old but it continues to be used widely.   
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 When IGRAs were introduced it was anticipated that they would rapidly replace TST. 
 Neither TST nor IGRAs have a high accuracy for predicting active TB.   
 Latest WHO recommendation are that either TST or IGRA can be used to test for LTBI.   
 TST will be clinically useful until more accurate tests become available.  
 
ABSTRACT 
Objective:  To make an informed viewpoint on the usefulness of Tuberculin Skin test (TST) compared to 
Interferon Gamma Release Assays (IGRAs) for diagnosis of Latent TB Infection (LTBI) in different 
geographical settings.  
Methods: We reviewed the current literature on TST compared to IGRA, including national 
implementation of WHO LTBI recommendations and retrospective data over the past 7 years at the National 
Institute for Infectious Diseases “L. Spallanzani” as indirect indicator of usage of both tests under actual 
programmatic conditions. 
Results: Current national guidelines vary considerably, reflecting the uncertainty and rapidly evolving 
evidence about the potential use of these tests. Data from Institute “L. Spallanzani” showed IGRA 
concordance in TST positive subjects only in 54.74% of subjects, while there was strong concordance 
between two tests in TST negative subjects (93.78%).   
Conclusion: Neither IGRAs nor TST can distinguish active TB from LTBI. TST will continue to be 
clinically useful in low and high TB endemic areas until more accurate and predictive tests will become 
available. Clinical judgment remains fundamental in choosing between IGRA/TST tests and interpreting 
their results.   
 
Introduction 
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Whilst the tuberculin skin test (TST) (better known as the Mantoux Test to older generation physicians), is 
over a century old, it continues to be used in high endemic TB settings as diagnostic tool for determining 
latent Mycobacterium tuberculosis (MTB) infection (LTBI) (1). WHO define latent tuberculosis infection 
as “a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no 
evidence of clinically manifest active TB”. The TST measures delayed type hypersensitivity (DTH) 
response to intradermal injection of purified protein derivative (PPD), a crude mixture of several 
mycobacterial antigens, which are common to M. tuberculosis, M. bovis BCG, and non-tuberculous 
mycobacteria (NTM). Thus, a positive TST test is of low specificity and cannot differentiate between M. 
tuberculosis infection, prior BCG vaccination, infection with, or exposure to NTM. It also has a low 
sensitivity in individuals with immunosuppression such as people living with HIV. Operational limitations 
of test include requirement for two visits up to 72 hours apart, between initial intradermal injection of PPD 
to reading the skin PPD-DTH response, reader variability, and the need for trained personnel to read the 
test results.  
 
Interferon-γ release assays versus TST 
While TST encompasses antigens recognized by a vast pool of circulating T lymphocytes, the two 
interferon-γ release assays (IGRAs), the QuantiFERON-TB ® assay (Cellestis Limited, Australia) and T 
SPOT-TB ® (Oxford Immunotec, UK), focus on interferon-γ responses to epitopes from two specific MTB 
complex associated antigens, namely ESAT-6 and CFP-10. When IGRAs were introduced into clinical 
practice a decade ago, it was anticipated that they would rapidly replace TST which would become 
redundant. The reasons were that: IGRAs do not cross-react with BCG, they are less likely to cross-react 
with NTM and they require only one health-care visit during which a blood sample is drawn and results can 
be available within 24 hours. Disadvantages of IGRAs are that they require blood samples and a laboratory 
to process them, quickly after collection (2). While hundreds of papers have been published on comparing 
performance of TST and IGRAs much remains unknown about the efficacy of IGRAs relative to TST due 
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methodological limitations, the lack of a compactor gold standard for detecting LTBI and the small sample 
size and inadequate statistical power (3).  IGRAs appear to have a higher specificity than TST in persons 
vaccinated with BCG, although they have similar sensitivity to TST.  
 
TST versus IGRAs for predicting the risk of LTBI progressing to active TB disease 
A large prospective cohort study in the United Kingdom showed that positive IGRAs were significantly 
better than the TST-10 mm and TST-5 mm strategies in predicting the development of active TB among 
high-risk individuals from TB-endemic countries. TST-5 mm identified a higher proportion of participants 
who progressed to active TB (64 [83%] of 77 tested) than all other tests and TST thresholds (≤75%) (4). 
Several published studies have addressed these issues with different results and conclusions: Pai and coll. 
reported a pooled specificity of 99% among non-BCG vaccinated and 96% among BCG-vaccinated low- 
risk groups (5). Vesembecth and colleagues assessed the diagnostic accuracy (21% of controls showed test 
results above 0.35 IU/mL) of the latest generation IGRA in low-incidence areas in Germany (6). In a recent 
meta-analysis by Sester and colleagues not restricting studies on specificity to low-risk groups (a situation 
that is closer to the clinical setting), the specificity of QFT-GIT was only 0.79 (95% CI 0.75–0.82). (7).   
Rangaka and colleagues   systematic review and meta-analysis showed neither TST nor IGRAs have a high 
accuracy for predicting active TB (8).   
 
Latest WHO guidelines for use of TST and IGRAs 
The WHO guidelines Group for developing the WHO LTBI management guidelines (WHO, 2018) utilized 
five IGRA and TST studies from high-TB incidence countries estimated pooled Risk Ratios for test 
positives and test negatives for each test and found RR 1.49 for TST and 2.03 for IGRA. They concluded 
that neither test  is better for predicting progression to active TB disease and that TST remains an acceptable 
option for children of less of five years old (1). In HIV-infected individuals, a recent review of comparative 
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data did not provide robust evidence to support the assertion that the IGRAs are superior to the TST when 
used in HIV infected subjects without evidence of active TB (9). 
Generic WHO recommendation are that either TST or IGRA can be used to test for LTBI. Persons with no 
known risk factors for TB may be considered for treatment of LTBI if they have a positive skin reaction to 
the TST of 15 mm or larger. 
There is no strong evidence that one test should be preferred over the other to predict progression to active 
TB disease. IGRAs or TST in clinical practice should be guided by considerations of availability, cost and 
benefits, and resources (1). European Centre for Disease Prevention and Control’s evaluation of cost-
effectiveness of screening, from the healthcare perspective, was in favor of using TST, and if positive 
followed IGRA (10). An official CDC health update highlighted higher costs associated at the use of the 
IGRA blood tests as substitute for TSTs (11). Other countries, such as England, recommend using TST in 
BCG- vaccinated subjects. (12)  
National guidelines for use of TST or IGRAs 
Current national guidelines vary considerably, reflecting the uncertainty and rapidly evolving evidence 
about the potential uses of these tests (13).  In deciding whether to use the TST, IGRAs individual clinical 
expertise and the best available local evidence are essential tools for developing local guidelines. At the 
National Institute for Infectious Diseases “L. Spallanzani” in Rome since several years, a protocol for the 
management of tuberculosis (available at http://www.inmi.it/protocolli_e_linee_guida.html), based on 
WHO and ECDC recommendations, was adopted. The protocol recommends the use of IGRAs tests in 
subjects vaccinated with BCG (or coming from countries where the vaccination is routinely performed), in 
immunosuppressed patients (HIV, especially if CD4 + <200/ mmc, or taking immunosuppressive drugs), 
children >5 years and, according to the clinician opinion, as a TST confirmation test. Observational 
routinely collected health data in the last 7 years have been evaluated as indirect indicator of  test’s 
performance under real-life conditions and are summarized hereafter as end-users’ report. 
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From January 2011 to November 2018, in 6,132 subjects TST (PPD-S 5UI) had been performed with 1,329 
positive tests after 72 hours (21.67%). Applying this protocol, IGRA (QuantiFERON-TB ®) test was 
performed in 346 subjects from this cohort, with 88 positive results (25,43%). Data reported in Table 1 
demonstrate clinical use of IGRA test as a confirmatory test in 60.40% of TST- subjects and in 39.60% of 
TST+ subjects. While IGRA concordance in TST+ve subjects was observed in 54.74% of subjects, data 
showed strong concordance between two tests in TST-ve subjects, in which group HIV/Immunosuppressed 
patients are mostly represented.  These data are consistent with the local protocol statement who suggest 
carefully evaluate negativity of TST/IGRA in immunosuppressed patients, especially in ruling out active 
TB.  In our experience, although not in a very large number of patients, IGRAs were able to identify 13 out 
of 209 individuals (6.22%) candidates to LTBI treatment who were TST negative. These data must be 
interpreted cautiously considering high variability of context in real life, and need to be confirmed by further 
studies.  In fact, choice of one test or both and interpretation of their results need to be defined considering 
the clinical or epidemiological characteristics of the subjects, available resources and turn-round time. 
 
Conclusion 
Clinical use of the TST as opposed to IGRAs should be according to availability of reagents, resources, 
national recommendations, specific clinical scenario. Clinical judgement remains fundamental in selecting 
the LTBI tests, interpreting the results of IGRA/TST tests. The ultimate test awaited is one that can more 
specifically distinguish active TB from LTBI. The use of IGRAs has increased in low TB endemic areas 
but TST will continue to be clinically useful in low and high TB endemic areas, until more predictive tests 
become available to allow for identification of individuals at the highest risk of progressing to developing 
active TB diseases. 
 
Conflicts of Interest: All authors declare no conflict of interest 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
Contributions 
FNL, AZ and GI conceived the idea and developed key concepts in the manuscript, contributed to the 
literature review, the first draft and revisions of the manuscript. GG, PMe, FP collected and analyzed data, 
contributed to the literature review, the first draft and revisions of the manuscript. SM, PMw, JC contributed 
to the original text and subsequent revisions of the manuscript. All authors read and approved the final 
manuscript. 
 
Ethical approval 
All enrolled patients provided written informed consent to the utilization of anonymous clinical data for 
research purpose approved by L. Spallanzani Institute Ethical Committee. 
 
Acknowledgements 
Authors GG, PMe, FNL, FP, and GI are grateful for support from the Italian Ministry of Health, grant 
Ricerca Corrente, Research program n. 4 Tuberculosis. Original data to evaluate in the real life the 
Concordance of TST and IGRA have been collected in the framework of the Ricerca Corrente funding. 
Authors SM, PMw, AZ and GI receive support from EDCTP2 grants  (RIA 2016E-1609-PANDORA-ID-
NET and EDCTP-RegNet2015-1104 EACCR2) supported under Horizon 2020, the European Union. 
 
AC
CE
PT
D M
AN
US
CR
IPT
9 
 
References 
1. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for 
programmatic management. Geneva: World Health Organization; 2018. fLicence: CC BY-NC-SA 3.0 IGO. 
Available at apps.who.int/iris/bitstream/10665/260233/1/9789241550239-eng.pd.  [Accessed November 
29, 2018]. 
2. Wilson FA, Miller TL, Stimpson JP. Mycobacterium Tuberculosis Infection, Immigration Status, 
and Diagnostic Discordance: A Comparison of Tuberculin Skin Test and QuantiFERON-TB Gold In-Tube 
Test Among Immigrants to the U.S.  Public Health Rep 2016; 131: 303-10. 
3. LoBue P A, Castro K G. Is it time to replace the Tuberculin skin test with a blood test?             JAMA 
2012; 308: 241-2. 
4. Abubakar I, Drobniewski F, Southern J, et al.  Prognostic value of interferon-γ gamma release 
assays and tuberculin skin test in predicting the development of active tuberculosis: the UK PREDICT 
tuberculosis cohort study. Lancet Infect Dis 2018; 18: 1077-87. doi: 10.1016/S1473-3099(18)30355-4.   
5. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent 
tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-84. 
6. Vesenbeckh SM, Schönfeld N, Mauch H, et al. The use of interferon gamma release assays in the 
diagnosis of active tuberculosis. Tuberc Res Treat 2012; 2012:768723. doi: 10.1155/2012/768723. 
7. Sester M, Sotgiu G, Lange C, et al. Interferon-γ release assays for the diagnosis of active 
tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-11.  
8. Rangaka MX, Wilkinson KA, Glynn JR. Predictive value of interferon-release assays for incident 
active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55. 
9. Overton K, Varma R, Post JJ. Comparison of Interferon-γ Release Assays and the Tuberculin 
SkinTest for Diagnosis of Tuberculosis in Human Immunodeficiency Virus: A Systematic Review. Tuberc 
Respir Dis 2018; 81: 59-72. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
10 
 
10. European Centre for Disease Prevention and Control. Use of interferon-gamma release assays in 
support of TB diagnosis. Stockholm: ECDC; 2011. Available at https://ecdc.europa.eu/en/publications-
data/public-health-guidance-use-interferon-gamma-release-assays-support-tb-diagnosis. [Accessed 
December 9, 2018]. 
11. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. IGRA Expert Committee. 
Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma 
Release Assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 
2010; 59: 1-25. 
12. National Institute for Health and Clinical Excellence. NICE guidelines: Tuberculosis; 13 January 
2016. Available at https://www.nice.org.uk/guidance/ng33/resources/tuberculosis-1837390683589. 
[Accessed November 25, 2018]. 
13. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-γ release assays for tuberculosis 
infection: concordance, discordance or confusion? Clin Microbiol Infect 2011; 17: 806-14. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
11 
 
Table 1. Concordance of TST and IGRA results among subjects referred at National Institute for 
Infectious Diseases Lazzaro Spallanzani in Rome 
 
 IGRA + IGRA - TOTAL 
TST+ n. (%) 75 (54.74%) 62 (45.26%) 137 (39.60%) 
BCG Vaccinated               45  
Clinician opinion              26 
HIV/Immunosuppressed    4 
Children > 5 years              0 
BCG Vaccinated                     39 
Clinician opinion                    22 
HIV/Immunosuppressed           1 
Children > 5 years                    0 
BCG vaccinated               84 
Clinician opinion             48                  
HIV/Immunosuppressed    5 
Children > 5 years             0 
TST- n. (%) 13 (6.22%) 196 (93.78%) 209 (60,40%) 
BCG Vaccinated                 2  
Clinician opinion                8 
HIV/Immunosuppressed     3 
Children > 5 years              0 
BCG Vaccinated                     74  
Clinician opinion                   102 
HIV/Immunosuppressed         20 
Children > 5 years                    0 
BCG Vaccinated               76  
Clinician opinion             110 
HIV/Immunosuppressed    23 
Children > 5 years               0 
IGRA n. (%) 
 
88 (25.43%) 258 (74.57%) 346 
 
 
TST: Tuberculin Skin Test 
IGRA: interferon-γ release assay (QuantiFERON-TB Gold In-Tube) 
BCG: Calmette Guèrin Bacillus 
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